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Background: Controversy remains concerning the impact of Ureaplasma on preterm
neonatal morbidity.
Methods: Prospective single-center study in very low birth weight infants <30
weeks’ gestation. Cord blood and initial nasopharyngeal swabs were screened for
Ureaplasma parvum and U. urealyticum using culture technique and polymerase chain
reaction. Neonatal outcomes were followed until death or discharge. Multi-analyte
immunoassay provided cord blood levels of inflammatory markers. Using multivariate
regression analyses, perinatal Ureaplasma exposure was evaluated as risk factor for
the development of bronchopulmonary dysplasia (BPD), other neonatal morbidities until
discharge and systemic inflammation at admission.
Results: 40/103 (39%) infants were positive for Ureaplasma in one or both specimens,
withU. parvum being the predominant species. While exposure toUreaplasma alone was
not associated with BPD, we found an increased risk of BPD in Ureaplasma-positive
infants ventilated ≥5 days (OR 1.64; 95% CI 0.12–22.98; p = 0.009). Presence of
Ureaplasma was associated with a 7-fold risk of late onset sepsis (LOS) (95% CI
1.80–27.39; p = 0.014). Moreover, Ureaplasma-positive infants had higher I/T ratios (b
0.39; 95% CI 0.08–0.71; p = 0.014), increased levels of interleukin (IL)-17 (b 0.16; 95%
CI 0.02–0.30; p = 0.025) and matrix metalloproteinase 8 (b 0.77; 95% CI 0.10–1.44;
p = 0.020), decreased levels of IL-10 (b −0.77; 95% CI −1.58 to −0.01; p = 0.043) and
increased ratios of Tumor necrosis factor-α, IL-8, and IL-17 to anti-inflammatory IL-10
(p = 0.003, p = 0.012, p < 0.001).
Conclusions: Positive Ureaplasma screening was not associated with BPD. However,
exposure contributed to BPD in infants ventilated ≥5 days and conferred an
increased risk of LOS and imbalanced inflammatory cytokine responses.
Keywords: Ureaplasma parvum, Ureaplasma urealyticum, preterm infants, VLBW, bronchopulmonary dysplasia,
late onset sepsis, neonatal outcome, inflammation
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INTRODUCTION
Although substantial therapeutic advances have continously
improved the survival of preterm infants, the incidence of
neonatal morbidity and sequelae has not declined (Stoll et al.,
2015). This is particularly due to the heightened susceptibility
of very immature preterm infants to severe infections and major
morbidities, such as bronchopulmonary dysplasia (BPD) (Stoll
et al., 2015). Colonization with Ureaplasma species (spp.) has
been associated with increased risk of BPD in preterm infants
(Viscardi and Hasday, 2009; Lowe et al., 2014), and there is
some evidence of additional implication in the pathogenesis
of intraventricular hemorrhage (IVH), necrotizing enterocolitis
(NEC) and retinopathy of prematurity (ROP) (Viscardi et al.,
2008; Kasper et al., 2011; Silwedel et al., 2017). Ureaplasma spp.
have been frequently isolated from amniotic fluid, cord blood and
respiratory tract samples of preterm infants who later developed
BPD (Viscardi and Hasday, 2009). Ureaplasma respiratory tract
colonization appears to contribute to pulmonary inflammation
and altered lung development (Viscardi and Hasday, 2009).
Intraamniotic detection of Ureaplasma spp. was shown to be
paralleled by intrauterine and fetal inflammatory response and
increased risk of adverse pulmonary and neurologic outcome in
preterm infants (Berger et al., 2009; Kasper et al., 2011; Glaser and
Speer, 2015; Sweeney et al., 2017). However, the clinical relevance
of detecting Ureaplasma spp. in microbiological specimens
of preterm infants remains subject of discussion. Ureaplasma
parvum (serovars 1, 3, 6, 14) and U. urealyticum (serovars 2,
4, 5, 7–13) are generally regarded as commensal bacteria being
isolated from 40 to 80% of urogenital tract samples of women of
reproductive age (Waites et al., 2005; Sweeney et al., 2017). For
reasons of low pathogenicity in children and adults, the presence
of Ureaplasma-driven inflammation and its impact on neonatal
morbidity have been discussed controversially (Volgmann et al.,
2005; Glaser and Speer, 2015). The present study aimed to
investigate whether early life exposure to Ureaplasma spp. is
associated with (i) the development of BPD, (ii) the development
of other neonatal morbidities until discharge, and (iii) systemic
inflammation at admission in a cohort of very low birth weight




Preterm infants with GA <30 weeks and birth weight <1,500 g
admitted to the tertiary neonatal intensive care unit at the
Children’s Hospital of Poznan, University of Medical Sciences,
Poland, were eligible for this prospective study conducted
between May 2014 and December 2015. Outborn infants as
well as infants with major congenital malformations, lack of
informed consent or absence of specimens for Ureaplasma
screening and/or analysis of cord blood inflammatory markers
were excluded. Among 202 infants eligible, 103 met the
primary inclusion criteria (Figure 1). Infants were categorized as
Ureaplasma-positive and negative depending on initial screening.
Infant data were entered into a computerized data sheet, verified
by two different investigators. Neonatal outcomes were followed
until death or discharge.
Outcome Definitions
BPD, the primary endpoint, was defined as requirement of
oxygen therapy for at least 28 days and classified according to
the need of supplemental oxygen at 36 weeks’ postmenstrual
age (Jobe and Bancalari, 2001). Predefined secondary endpoints
comprised respiratory distress syndrome (RDS) ≥ grade 3, IVH
≥ grade 3, periventricular leukomalacia (PVL), NEC ≥ stage
2, ROP ≥ stage 3, late onset sepsis (LOS), meningitis and
death prior to discharge. Diagnosis of RDS referred to clinical
and radiographic features, and the requirement of supplemental
oxygen. IVH was diagnosed by means of cranial ultrasound and
graded according to the Papile classification (Papile et al., 1978).
PVL was defined as bilateral cystic lesions in periventricular
areas documented in coronal and parasagittal ultrasound scans
performed > 28 days after birth (Perlman et al., 1996). NEC
was diagnosed by clinical and radiological signs according to
Bell’s staging (Bell, 1978). ROP was determined following the
international classification (International Committee for the
Classification of Retinopathy of Prematurity, 2005). Diagnosis of
LOS required clinical and laboratory signs of systemic infection
at>72 h of age, positive blood culture and antibiotic treatment≥
5 days. Meningitis was defined by clinical and laboratory signs of
systemic infection, abnormal cerebrospinal fluid parameters, and
positive cerebrospinal fluid culture.
Sample Collection and Laboratory
Methods
Umbilical cord blood samples were taken immediately after
delivery using an aseptic technique. The needle puncture site
was disinfected with a 0.1% aqueous solution of octenidine
with phenoxyethanol (Octenisept R©, Schuelke & Mayr GmbH,
Germany) applied by means of a spray and saturated swabs
thereafter. The site was allowed to dry for 1min before cord blood
was drawn using a sterile, unheparinized syringe. ForUreaplasma
culture, 0.5mL cord blood was immediately inoculated into 2mL
10B broth (Thermo Fisher Scientific, Germany). Nasopharyngeal
swabs obtained within 2 h after birth using sterile transport swabs
(Copan, Italy) were also immediately placed in the commercially
available ready-to-use tubes providing 2mL of 10B broth. Swab
and liquid cultures were incubated at 37◦C in 5% CO2/air
for 10 days and monitored daily. If color change occurred,
inoculums of 0.2mL were plated on A8 agar to confirm positive
broth. All cord blood samples and swabs were additionally
investigated for DNA of U. parvum and U. urealyticum using
commercially available kits for DNA extraction and amplification
according to the manufacturer’s protocol (AmpliSens R© DNA-
sorb-B, AmpliSens R© U. parvum/U. urealyticum-FRT; Ecoli Ltd.,
Slovak Republic). An mba-based real-time PCR approach was
used to discriminate U. parvum serovars (Otgonjargal et al.,
2018). Routine cord blood and nasopharyngeal swab cultures
were assessed using the Bactec Peds Plus/F blood culture
system (bioMérieux, Poland), selective agars and the Vitek R© MS
system (bioMérieux).
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FIGURE 1 | Summary of preterm infants eligible, enrolled in the study and included in the final analysis.
Cord blood leukocyte counts, immature/total neutrophil (I/T)
ratios and C-reactive protein levels were analyzed within 2 h after
birth. For quantification of TNF-α, IL-1β, IL-8, IL-12, IL-17, IL-
10, IL-1ra, IFN-γ, IP-10, MMP-8/9, MIP-1α/β, MCP-1, VEGF,
G-CSF, ICAM-1, and VCAM-1, serum aliquots of ≥0.2mL were
stored at −80◦C until analysis. Multianalyte immunoassay was
carried out using Luminex R© multiplex kits and the xPonent R©
software (Merck group, Germany) as described before (Glaser
et al., 2017, 2018a,b).
Maternal Screening and Placental
Pathology
Maternal vaginal screening was assessed at admission as part of
routine clinical care. Bacterial vaginosis was defined according to
the Nugent criteria (Nugent et al., 1991). Placental examination
was part of the research study and was conducted after written
informed consent was obtained. Histopathological investigation
was performed by 2 independent pathologists at the Institute of
Pathology, Poznan University of Medical Sciences, following a
published protocol (Rogers et al., 2002).
Statistical Analyses
Sample size was determined using an approximate sample
size formula for studies with dichotomous outcomes (Schulz
and Grimes, 2005). Based on preliminary data reporting on
incidences of BPD in Ureaplasma colonized preterm infants
(Lowe et al., 2014) and baseline BPD rates of about 25% in
infants <32 weeks’ GA in Poland (Fanaroff et al., 2007; Gortner
et al., 2011), we calculated that minimum 38 infants per study
group needed to be enrolled and included in the final analysis
to detect a 2-fold risk of BPD with α = 0.05 and power.80.
Infant characteristics were analyzed descriptively, and tested for
differences using X2, Fisher’s exact test and Cramér’s V for
qualitative variables, Q-Q plots, unpaired t, and Mann-Whitney
U test for quantitative variables. Bivariate analyses using X2,
Fisher’s exact test and Cramér’s V and multivariate logistic
regressions were performed to test for associations between
Ureaplasma exposure and primary and secondary outcomes.
Covariates offered to the models were GA, birth weight, male sex,
singleton status, antenatal corticosteroids, antenatal antibiotics,
antenatal macrolides, preterm premature rupture of membranes
>12 h, histologic chorioamnionitis, vaginal delivery, vaginal
Ureaplasma/GBS/other bacteria/Candida, surfactant treatment,
ventilation days, supplemental oxygen days, patent ductus
arteriosus requiring treatment as well as presence of and
duration of central venous lines. Covariates were included if
significant at p < 0.10 in preceding analyses using X2, Fisher’s
exact test and Cramér’s V, Q-Q plots, unpaired t and Mann-
Whitney U. Subgroup analyses were performed on Ureaplasma-
positive infants and Ureaplasma-negative infants, respectively,
ventilated< or≥5 days using the same approach. Corresponding
bivariate and stepwise multivariate linear regression analyses
examined the relationship between Ureaplasma exposure and
cord blood inflammatory markers. A p-value < 0.05 was
considered significant. Analyses were performed using the
Statistical Package of Social Sciences (SPSS) software, version 24
(IBM, Germany).
RESULTS
During the study period, 202 VLBW infants born at <30 weeks
GA were admitted to the Poznan NICU. One hundred and three
infants met the inclusion criteria and were included in the final
analysis (Figure 1). Among these, 40 (39%) were culture/PCR
positive for Ureaplasma spp. in one or both specimens and
63 (61%) were Ureaplasma-negative. The Ureaplasma-positive
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FIGURE 2 | (A) Numbers of Ureaplasma-negative infants as well as U. parvum-positive and U. urealyticum-positive infants given for each week of gestation (assessed
as completed weeks). (B) Distribution of U. parvum serovars in Ureaplasma-positive swab and cord blood specimens.
group comprised 32 infants with positive nasopharyngeal swabs,
16 infants with cord blood positive for Ureaplasma and 8
infants with detection of Ureaplasma spp. in both specimens.
Quantitative real-time PCR detected Ureaplasma spp. in 40/40
Ureaplasma-positive study infants, culture technique spotted
Ureaplasma in 11/40. Being detected in 33/40 (83%)Ureaplasma-
positive infants, U. parvum was the predominant species. U.
urealyticum was found in 7/40 infants, 3/40 infants carried
both species. Differentiation of U. parvum serovars revealed
different distribution patterns in swab and cord blood specimens
(Figure 2). Serovar differentiation of U. urealyticum was not
available. Detection of Ureaplasma was more frequent in infants
with a history of vaginal delivery (p = 0.024) and maternal
vaginal colonization with Ureaplasma (p = 0.003) and Candida
spp. (p = 0.026) (Table 1). Additionally, Ureaplasma-positive
and negative study infants differed in terms of central venous
lines present, with a higher number of infants with a central
venous catheter in the Ureaplasma-negative group (p = 0.006).
Clinical characteristics otherwise did not differ (Table 1). None
of the infants had a positive routine cord blood culture. Routine
cultures of initial nasopharyngeal swabs detected Candida
spp., Staphylococcus epidermidis, Staphylococcus haemolyticus,
Staphylococcus hominis, Streptococcus anginosus and Gardnerella
vaginalis in 23 and 22% of infants, respectively (Table 1).
Bivariate and stepwise multivariate logistic regression analyses
were used to test the primary hypothesis of increased BPD
rates in Ureaplasma-positive infants and the association between
Ureaplasma exposure and secondary endpoint measures. On
bivariate analysis, BPD rates did not differ among both study
groups (p = 0.218) (Table 2). Analyses including BPD severity
(p = 0.629) and the compound measure moderate/severe BPD
did not detect a significant correlation either (p = 0.374).
Covariates independently associated with BPD were ventilation
days (p = 0.039) and supplemental oxygen days (p = 0.032).
Subgroup analysis was performed comparing Ureaplasma-
positive infants with a history of <5 days of mechanical
ventilation (n = 20) with Ureaplasma-positive infants ventilated
≥5 days (n = 20), to examine whether perinatal Ureaplasma
exposure interacts withmechanical ventilation. Bivariate analyses
documented increased rates of BPD in Ureaplasma-positive
infants ventilated ≥5 days (87 vs. 28%, p = 0.001), and
adjusted analysis confirmed increased odds of BPD in infants
with positive Ureaplasma screening (OR 1.64; 95% CI 0.12–
22.98; p = 0.009). Covariates included in the model were GA,
birth weight, male sex, vaginal delivery, antenatal antibiotics,
vaginal Ureaplasma, RDS ≥grade 3, surfactant administration,
ventilation and supplemental oxygen days. Birth weight was
an independent predictor of BPD in this model (OR 0.99;
95% CI 0.98–1.00; p = 0.007). Analyses in the Ureaplasma-
negative group documented BPD rates of 70% in infants
ventilated ≥5 days compared to 48% in infants ventilated
<5 days (p= 0.156).
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TABLE 1 | Prenatal, perinatal, and postnatal characteristics of study infants.







26 (23–29) 26 (22–29) 0.919
Birth weight (g), mean (range) 912 (460–1,490) 872 (440–1485) 0.394
Sex (male), n (%) 23 (58%) 42 (67%) 0.488
Singleton, n (%) 31 (78%) 48 (76%) >0.999
Antenatal steroids, n (%) 38 (95%) 61 (97%) >0.999
Antenatal antibiotics, n (%) 27 (68%) 45 (71%) 0.889
Antenatal macrolides, n (%) 21 (53%) 30 (48%) 0.416
PPROM > 12 h, n (%) 13 (33%) 22 (35%) >0.999
Histologic chorioamnionitis,
n (%)b
21 (53%) 28 (44%) 0.405
Vaginal delivery, n(%) 20 (50%) 16 (25%) 0.023*†
Vaginal Ureaplasma, n (%) c 21 (53%) 15 (24%) 0.004**‡
Vaginal GBS, n (%)d 3 (8%) 3 (5%) 0.502
Bacterial vaginosis, n (%)e 1 (3%) 2 (3%) >0.999
Vaginal Candida, n (%) 13 (33%) 8 (13%) 0.020*#
Other microbes
nasopharyngeally, n (%)
9 (23%) 14 (22%) >0.999
Surfactant administration,
n (%)
27 (68%) 44 (70%) 0.731
Ventilation days, mean (range) 19.1 (0–149) 20.2 (0–84) 0.360
Supplemental oxygen days,
mean (range)
14.8 (0–35) 16.9 (0–60) 0.677
PDA requiring treatment, n (%) 9 (23%) 24 (38%) 0.201
Presence of central venous
line, n (%)
25 (63%) 55 (87%) 0.012*##
Central venous line days,
mean (range)
11.2 (2–21) 12.7 (3–37) 0.401
aPearsons’s chi-square (X2 ) and Fisher’s exact test for qualitative variables. Q-Q plots,
unpaired t and Mann-Whitney U test for quantitative variables.
*p < 0.05, **p < 0.01.
†
Cramér‘s V 0.256 (p 0.014), Cramér‘s V 0.417 (p 0.003),
#Cramér‘s V 0.241 (p 0.011), ##Cramér‘s V 0.322 (p 0.01).
bHistopathological examination performed in 89 placentas.
cData available in 89 mothers. dData available in 91 mothers. eNugent score ≥ 7.
GBS, group B Streptococcus; PDA, patent ductus arteriosus; PPROM, preterm
premature rupture of membranes.
Testing the association between perinatal Ureaplasma
exposure and secondary outcomes, we found a tendency toward
increased rates of LOS in Ureaplasma-positive infants (Table 2).
On multivariate regression adjusting for confounding variables,
detection of Ureaplasma spp. was associated with a 7-fold
risk of LOS (Table 3). There was no difference in the onset of
sepsis among Ureaplasma-positive and negative study infants
[mean day of life 17.0 (range 6–51) vs. 19.8 (7–52), p = 0.355].
Moreover, both groups did not differ in terms of exposure
to a prior empiric antibiotic therapy at admission, that was
mostly limited to the first 48–72 h of life. No infant had more
than one episode of sepsis. Blood cultures of Ureaplasma-
positive infants with LOS were positive for Escherichia coli (4
infants), Staphylococcus haemolyticus (3 infants), Staphylococcus
aureus and Staphylococcus epidermidis. Infecting organisms in
TABLE 2 | Bivariate analyses testing for associations between perinatal exposure
to Ureaplasma and primary and secondary outcome measures.





BPD totalb 18/36 (50%) 32/56 (57%) 0.218
BPDb 0.629
– Mild 6/36 (17%) 12/56 (21%)
– Moderate 8/36 (22%) 12/56 (21%)
– Severe 4/36 (11%) 8/56 (14%)
RDS ≥ grade 3 14 (35%) 28 (44%) 0.481
IVH ≥ grade 3 11 (28%) 17 (27%) 0.949
PVLc 5/36 (14%) 10/56 (18%) 0.487
NEC ≥ stage 2 4 (10%) 9 (14%) 0.536
ROP ≥ stage 3c 3/36 (8%) 7/56 (13%) 0.478
Late onset sepsis 10 (25%) 6 (10%) 0.060†
Meningitis 0 (0%) 2 (3%) 0.288
Death prior to discharge 4 (10%) 8 (13%) 0.602
Values are expressed as numbers and proportions. aPearsons’s chi-square
(X2 ), Fisher’s exact test and Cramér’s V.
†
Cramér’s V 0.211 (p 0.048).
bDiagnosis assessed in 92 infants at 36 weeks PMA—based upon the criterion of
supplemental oxygen for at least 28 days and classified according to the amount of
supplemental oxygen at 36 weeks PMA (11 infants died prior to 28 days of life and prior
to 36 weeks PMA).
cData available in 92 infants.
BPD, bronchopulmonary dysplasia; IVH, intraventricular hemorrhage; PVL, periventricular
leukomalacia; PMA, postmenstrual age; NEC, necrotizing enterocolitis; RDS, respiratory
distress syndrome; ROP, retinopathy of prematurity.
TABLE 3 | Stepwise multivariate logistic regression analysis examining the
correlation between Ureaplasma exposure and late onset sepsis.
Outcome Late onset sepsis p-valuea
Independent variables OR (95% CI)
Presence of Ureaplasma spp. 6.955 (1.801–27.390) 0.014*
Sex (male) 0.297 (0.078–1.133) 0.076
Vaginal delivery 0.201 (0.039–1.019) 0.053
Vaginal Ureaplasma spp. 0.981 (0.231–4.169) 0.981
Vaginal Candida spp. 0.610 (0.110–3.390) 0.572
Presence of central venous line 0.630 (0.146–2.714) 0.535
aCovariates offered to the model were independent variables significant at p < 0.10 in
preceding bivariate analyses. *p < 0.05.
CI, confidence interval; OR, odds ratio.
Ureaplasma-negative infants were Escherichia coli, Enterococcus
faecalis, Acinetobacter baumanii, Streptococcus agalactiae,
Staphylococcus haemolyticus, and Candida albicans. Ureaplasma-
positive infants with and without LOS did not significantly differ
in primary or secondary outcome measures or in terms of species
and serovar isolated. U. parvum was present in 70% of infants
with LOS (serovar 3: 57%, serovar 6: 28%, serovar 1: 14%). In one
infant both species were detected.
Exposure to Ureaplasma spp. was not associated with the
development of RDS ≥grade 3, IVH ≥grade 3, PVL, NEC
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FIGURE 3 | Differences in cord blood serum levels of IL-17 (A) and IL-10 (B), ratios of pro-inflammatory cytokines to anti-inflammatory IL-10 (C) and I/T ratios (D)
among Ureaplasma-positive and Ureaplasma-negative infants on bivariate analysis (*p < 0.05, **p < 0.01, ***p < 0.001).
≥stage 2, ROP ≥stage 3, meningitis and death prior to
discharge (Table 2; characteristics of all infants who died prior to
discharge and causes of death given in Supplementary Table S1).
However, subgroup analyses comparing Ureaplasma-positive
infants ventilated<5 days with those ventilated≥5 days revealed
increased rates of IVH ≥grade 3 and PVL in the latter (IVH
≥grade 3: 0 vs. 55%, p < 0.001; PVL: 0 vs. 29%, p = 0.016). On
multivariate regressions controlling for GA, birth weight, vaginal
Ureaplasma, ventilation days, RDS ≥grade 3 and patent ductus
arteriosus requiring treatment and GA, birth weight, surfactant
administration and ventilation days, respectively, co-exposure to
Ureaplasma and mechanical ventilation ≥5 days was associated
with increased odds of IVH ≥grade 3 (OR 3.36; 95% CI 0.70–
16.617; p = 0.030). The correlation with PVL was no longer
significant (OR 0.1; 95% CI 0.01–1.09; p = 0.059). Low GA (OR
0.27; 95% CI 0.08–0.93; p= 0.037) and RDS≥grade 3 (OR 25.53;
95% CI 1.18–554.41; p = 0.040) were independent risk factors
for IVH ≥grade 3. Analyses in the Ureaplasma-negative group
revealed rates of IVH ≥grade 3 of 18% in infants ventilated < 5
days and 32% in infants with a history of mechanical ventilation
≥5 days (p = 0.205) as well as similar rates of PVL in both
subgroups (13 vs. 15%, p= 0.663).
Cord blood levels of inflammatory markers were compared
among Ureaplasma-positive and Ureaplasma-negative infants.
We found higher I/T ratios and increased levels of IL-
17, but decreased levels of IL-10 and increased ratios of
pro-inflammatory cytokines to anti-inflammatory IL-10 in the
former group (Figure 3). Moreover, Ureaplasma-positive infants
had higher levels of MMP-8 (p= 0.024) and ICAM-1 (p= 0.041)
and showed a trend toward decreased levels of IL12p40 in
cord blood (p = 0.089). Stepwise multivariate linear regressions
adjusting for confounding confirmed an association between
positive Ureaplasma screening and increased I/T ratios and
levels of IL-17 and MMP-8, decreased levels of IL-10 and
increased ratios of TNF-α, IL-8, and IL-17 to IL-10 (Table 4).
Lower GA and histologic chorioamnionitis were independent
predictors of increased cord blood levels of IL-17 and/or MMP-
8, respectively. The impact of preterm premature rupture of
membranes >12 h on IL-8/IL-10 ratios in cord blood was of
borderline significance (Table 4).
DISCUSSION
With improving care options but enduring occurrence of
relevant complications in very immature preterm infants, it is
of considerable importance to elucidate whether Ureaplasma
spp. are harmless commensals or true pathogens in this
cohort (Volgmann et al., 2005; Glaser and Speer, 2015).
In the present study, 39% of infants <30 weeks’ GA and
<1,500 g were positive for Ureaplasma at initial screening.
Detection of Ureaplasma spp., however, was not associated
with BPD development, rejecting our primary hypothesis. In
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TABLE 4 | Inflammatory markers associated with positive Ureaplasma screening adjusted for confounding variables.
Inflammatory marker Predictor Regression coefficient b
(95% CI)
p-valuea
I/T ratio Presence of Ureaplasma spp. 0.394 (0.082 to 0.707) 0.014*
Vaginal delivery 0.063 (−0.069 to 0.194) 0.343
Vaginal Ureaplasma spp. 0.167 (0.051 to 0.283) 0.626
Vaginal GBS 0.185 (0.004 to 0.279) 0.271
Vaginal Candida spp. −0.098 (−0.256 to 0.06) 0.218
IL-17b Presence of Ureaplasma spp. 0.159 (0.021 to 0.298) 0.025*
GA −0.035 (−0.07 to −0.001) 0.044*
Vaginal delivery 0.116 (−0.024 to 0.256) 0.104
Histologic chorioamnionitis 0.096 (−0.032 to 0.224) 0.138
IL-10b Presence of Ureaplasma spp. −0.767 (−1.582 to −0.010) 0.043*
Vaginal delivery 0.192 (−0.502 to 0.980) 0.65
Vaginal Ureaplasma spp. −0.101 (−0.852 to 0.711) 0.821
Vaginal Candida spp. −0.214 (−1.15 to 0.722) 0.50
MMP-8b Presence of Ureaplasma spp. 0.77 (0.104 to 1.436) 0.020*
GA −0.272 (−0.439 to −0.104) 0.002**
Vaginal delivery 0.281 (−0.493 to 1.054) 0.471
Vaginal Ureaplasma spp. 0.345 (−0.328 to 1.019) 0.31
Vaginal Candida spp. −0.494 (−1.296 to 0.308) 0.223
Antenatal antibiotics 0.463 (−0.237 to 1.162) 0.191
Histologic chorioamnionitis 1.026 (0.411 to 1.641) 0.001**
Ratio TNF-α/IL-10b Presence of Ureaplasma spp. 1.249 (0.441 to 2.056) 0.003**
Vaginal delivery −0.01 (−0.763 to 0.742) 0.978
Vaginal Candida spp. −0.121 (−0.998 to 0.757) 0.757
Ratio IL-8/IL-10b Presence of Ureaplasma spp. 1.309 (0.293 to 2.325) 0.012*
Vaginal delivery 0.116 (−0.024 to 0.256) 0.256
Vaginal Ureaplasma spp. 0.016 (−0.637 to 0.67) 0.961
Vaginal Candida spp. −0.399 (−1.463 to 0.665) 0.457
PPROM > 12 h 2.336 (−0.007 to 4.68) 0.051
Ratio IL-17/IL-10b Presence of Ureaplasma spp. 1.794 (0.818 to 2.77) <0.001***
Vaginal delivery 0.135 (−0.75 to 1.019) 0.762
Vaginal Ureaplasma spp. 0.04 (−0.706 to 0.827) 0.928
Vaginal Candida spp. −0.399 (−1.463 to 0.665) 0.457
aStepwise multi-variate linear regression analyses.
bTransformed logarithmically (LN(x)).
CI, confidence interval; GA, gestational age. *p < 0.05, **p < 0.01, ***p < 0.001.
contrast, we found an increased risk of BPD in Ureaplasma-
positive infants co-exposed to mechanical ventilation ≥5 days.
Positive screening forUreaplasma, moreover, was associated with
increased odds of LOS and imbalanced cytokine ratios pushed
toward pro-inflammation.
There is a number of epidemiologic data indicating an
association between Ureaplasma respiratory tract colonization
and the development of BPD (Viscardi and Hasday, 2009; Lowe
et al., 2014). In contrast, several other studies did not confirm
this correlation on adjusted analyses (van Waarde et al., 1997;
Patterson et al., 1998; Sung et al., 2011; Payne et al., 2012). In the
present investigation, we observed high overall rates of BPD, and
we can only speculate on the reasons. With low GA and low birth
weight being strong predictors of BPD (Stoll et al., 2010; Isayama
et al., 2012; Jobe, 2016), enrolled infants were at increased risk
of developing BPD per se. The observed BPD rates may further
owe to the inclusion of those infants who received supplemental
oxygen for ≥28 days but were breathing room air at 36 weeks’
postmenstrual age. Depending on the characteristics of a study
cohort and the underlying definition of BPD, reported incidences
may vary significantly (Lowe et al., 2014). Rates of BPD, defined
as oxygen supplementation at 36 weeks’ postmenstrual age,
ranged from 10 to 25% among preterm infants <32 weeks’ GA
born in different regions of Central Europe (Gortner et al., 2011),
and ranged from 12 to 15% among VLBW infants followed in the
Canadian, Israeli and Japanese neonatal networks (Isayama et al.,
2012; Klinger et al., 2013). In contrast, BPD rates were as high as
68% in the NICHD Neonatal Research Network, when including
infants who were breathing room air at 36 weeks’ postmenstrual
age (Stoll et al., 2010). It is noteworthy, however, that we observed
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a high number of ventilation days in the present study, most
likely, due to the restricted use of early non-invasive respiratory
support. Mechanical ventilation has been acknowledged as a
major postnatal determinant of BPD (Jobe and Bancalari, 2001;
Jobe, 2016), and was an independent predictor of BPD in our
study. Although both groups did not differ in terms of ventilation
days, a particularly strong impact of mechanical ventilation may
have masked the effects of less strong predictors.
In contrast to Ureaplasma exposure alone, co-exposure to
Ureaplasma spp. and mechanical ventilation ≥5 days was
associated with BPD outcome. These data support previous
reports of increased risk of moderate/severe BPD in preterm
infants with Ureaplasma-positive tracheal aspirates or gastric
fluid specimens and mechanical ventilation for any duration
and mechanical ventilation ≥14 days, respectively (Sung et al.,
2011; Inatomi et al., 2012). Data from a preterm baboon
model suggest that antenatal Ureaplasma exposure contributes
to early lung fibrosis in conjunction with postnatal mechanical
ventilation (Viscardi et al., 2006). There is substantial evidence
that mechanical ventilation may interact with antenatal and/or
postnatal infection to further increase the risk of BPD in
preterm infants (Van Marter et al., 2002; Lahra et al., 2009;
Balany and Bhandari, 2015). Our findings suggest that early
life exposure to Ureaplasma spp. and prolonged mechanical
ventilation may synergistically contribute to the development
of BPD. Of note, according to the present data, co-exposure to
Ureaplasma spp. and mechanical ventilation ≥5 days may also
increase the risk of high-grade IVH in very immature preterm
infants. Several case reports and some former studies suggested
an implication of Ureaplasma spp. in the pathogenesis of IVH
and adverse neurologic outcome (Viscardi et al., 2008; Berger
et al., 2009; Kasper et al., 2011; Glaser and Speer, 2015), with
neonatal systemic and central nervous system inflammation
being potential underlying mechanisms (Viscardi et al., 2008;
Glaser and Speer, 2015). We confirm and extend those works
and discuss thatUreaplasma-driven inflammation may modulate
neonatal respiratory and neurologic outcome in conjunction with
a second postnatal injurious hit.
Inflammation has been acknowledged as a common pathway
and principle mechanism in the multifactorial pathogenesis of
BPD (Groneck et al., 1994; Jobe and Bancalari, 2001; Balany
and Bhandari, 2015). While it remains debated whether or not
chorioamnionitis represents a risk factor for BPD (Thomas and
Speer, 2011; Hartling et al., 2012), persistent perinatal lung
inflammation and postnatal infection have been identified as
independent determinants (Groneck et al., 1996; Van Marter
et al., 2002; Lahra et al., 2009; Balany and Bhandari, 2015).
The present study indicates that Ureaplasma spp. effectively
induce pro-inflammatory immune responses, but might not
stimulate anti-inflammatory responses in VLBW infants and,
thus, promote cytokine imbalances pushed toward a pro-
inflammatory state. Our findings support data from previous
studies documenting increased expression of pro-inflammatory
mediators in airway secretions, serum and amniotic fluid
specimens of preterm infants colonized with Ureaplasma spp.
(Groneck et al., 1996; Patterson et al., 1998; Viscardi and
Hasday, 2009), and data from in vitro models documenting
Ureaplasma-driven pro-inflammatory responses in macrophages
and neonatal monocytes (Manimtim et al., 2001; Viscardi
and Hasday, 2009; Glaser et al., 2017, 2018a,b). Of note,
bronchoalveolar lavage samples of preterm infants with BPD
revealed diminished levels of IL-10, indicating a role for
imbalanced inflammatory responses in the pathogenesis of BPD
(Jones et al., 1996). In vitro studies reported missing IL-10
expression and imbalanced cytokine ratios pushed toward pro-
inflammation in Ureaplasma-stimulated neonatal monocytes
(Manimtim et al., 2001; Glaser et al., 2017). The current data
may provide additional evidence of a role for Ureaplasma in
dysregulated neonatal inflammation.
It is of particular interest, that preterm infants positive for
Ureaplasma were more likely to develop LOS in the present
study. In general, very immature preterm infants are at increased
risk of LOS for reasons of immature immunity as well as
exposure to a variety of partly interwoven risk factors, such as
invasive interventions like central venous lines and mechanical
ventilation, parenteral nutrition and delayed initiation of enteral
feeding, colonization with LOS-associated microorganisms as
well as prior antibiotic treatment or comorbidities of prematurity
like PDA and NEC (Boghossian et al., 2013; Dong et al., 2019).
The present analysis controlled for the majority of these risk
factors. Central venous lines, of note, were less present in infants
stratified to the Ureaplasma-positive study group. Study groups
did not differ in terms of initial empiric antibiotic therapy.
However, data on antibiotic treatment in the course of hospital
stay and results of weekly routine microbiological screening
were not assessed. Despite these limitations, the present results
may indicate immunomodulatory features of Ureaplasma spp.
in the event of secondary bacterial infection, that might drive
adverse outcome. This hypothesis adds to data from a preterm
sheep model and in vitro studies. While monocytes derived
from animals with acute (7 day) Ureaplasma infection showed
augmented cytokine responses to secondary stimulation with E.
coli lipopolysaccharide (LPS) in vitro, monocytes isolated from
animals with chronic (70 day) infection displayed decreased
responsiveness to secondary LPS stimulation (Kallapur et al.,
2011). In vitro studies of acute Ureaplasma infection in neonatal
and adult monocytes documented a differential modulation of
cytokine responses in the event of co-infection with E. coli LPS
(Manimtim et al., 2001; Glaser et al., 2017, 2018a). Moreover,
U. parvum and U. urealyticum were shown to alter Toll-like
receptor 2 and 4 expression and to suppress antimicrobial
peptide expression in human monocytes in vitro (Xiao et al.,
2014; Glaser et al., 2017). Given our current findings, we
speculate that immunomodulatory capacities of Ureaplasma
may affect preterm immune homeostasis in specific ways,
promoting imbalanced neonatal inflammation on the one hand
and increasing susceptibility to secondary bacterial infection on
the other hand. Time and duration of Ureaplasma exposure
might be key to the nature of immune alteration. In fact,
positive Ureaplasma screening at admission may reflect chronic
prenatal challenge to the organism in one infant and rather
acute exposure in another. Moreover, a phase of Ureaplasma-
driven inflammation might be followed by a refractory stage.
This sequence is known from a transiently altered immune state
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referred to as “endotoxin tolerance” (López-Collazo and Del
Fresno, 2013). Pathogen-pathogen or polymicrobial interaction
as well as host genetics or maturity-related host immune function
may additionally contribute to individual outcomes.
Detection rates of Ureaplasma in the present study are
in accordance with colonization rates of 24–52% reported in
preterm infants <32 weeks’ GA (van Waarde et al., 1997; Waites
et al., 2005; Viscardi and Hasday, 2009; Sung et al., 2011; Payne
et al., 2012). Discrepancy to clinical studies reporting lower
detection rates in preterm infants may be due to differences
in study design and study cohorts, site of sampling and, in
particular, the diagnostic and statistical methods applied. It
was not until the introduction of molecular techniques that
detection of Ureaplasma spp. improved and detection frequency
increased (Oh et al., 2010; Xiao et al., 2010). Sensitivity and
specificity has been shown to be much higher for PCR analysis.
Culture technique alone often misses a significant amount of
Ureaplasma-positive samples (Oh et al., 2010). However, given
that the screening for Ureaplasma was limited to cord blood
and nasopharyngeal swabs obtained at admission, this study
still may have missed a certain amount of Ureaplasma-positive
infants. A very recent investigation reported on increased yield
ofUreaplasma detection by collecting specimens at different time
points (Brand et al., 2018).
Few previous studies on Ureaplasma colonization in preterm
infants indicated an inverse relationship between colonization
and GA, with highest detection rates in infants 25–27 weeks
and <26 weeks, respectively (van Waarde et al., 1997; Sung
et al., 2011). In our cohort, we found similar detection rates
independent of GA. Exclusion of infants >30 weeks’ GA
might have accounted for this discrepancy. Reports on vertical
transmission rates of Ureaplasma spp. in pregnancy have
documented discrepant percentages, ranging from 15 to 88%,
and have also pointed toward an inverse relationship with GA
(Sánchez and Regan, 1990; Alfa et al., 1995; Chua et al., 1999;
Kafetzis et al., 2004). In the present study, maternal cultures were
not subject of speciation and serovar differentiation. Conclusions
on potential transmission rates could not be provided.
So far, little is known about differences in virulence at
the level of Ureaplasma species or among individual serovars
(Viscardi and Hasday, 2009; Silwedel et al., 2017; Sweeney et al.,
2017). Moreover, there is only scarce data on virulence factors
potentially related to disease manifestation (Abele-Horn et al.,
1997; Sung et al., 2011; Xiao et al., 2011a; Paralanov et al., 2012;
Uchida et al., 2013; Payne et al., 2014; Sweeney et al., 2017).
While U. parvum has been associated with chorioamniotis and
preterm labor in some investigations (Robertson et al., 1986; Kim
et al., 2003; Cox et al., 2016; Sweeney et al., 2017), other studies
failed to identify serovars more often associated with adverse
pregnancy outcome and invasive urogenital tract diseases (Xiao
et al., 2011a; Paralanov et al., 2012). A number of studies in
preterm infants at risk for BPD documented a predominance
of U. parvum in clinical isolates (Katz et al., 2005; Oue et al.,
2009; Payne et al., 2010, 2012, 2014; Sung et al., 2011; Winters
et al., 2013). Predominance of U. parvum in the current study
is in accordance with these previous observations. There is only
one study reporting on a predominance of U. urealyticum and
an increased risk of BPD in colonized infants (Abele-Horn et al.,
1997). In another study, simultaneous colonization with both
species was more frequent in preterm infants with the later
development of BPD (Katz et al., 2005). So far, no other study has
identified an association between neonatal outcome and isolation
of a particular Ureaplasma species or serovar. The small number
of U. urealyticum-positive infants in our cohort did not allow
to test for differences in neonatal outcome at the species level.
However, serovar 3 and 6 accounted for>90% ofU. parvum swab
and serovar 1 for >60% of cord blood isolates. While serovar
6 was not isolated from cord blood, serovar 14 was exclusively
found in those specimens. This study is the first to report on
potential differences of U. parvum serovar distribution in swab
and blood samples. In one previous study in preterm infants
assessing respiratory tract specimens, serovar 3 and 6 accounted
for 96% of U. parvum respiratory isolates (Sung et al., 2011).
Further data are essential to gain a better understanding of
individual serovars and potential associations with colonization
and/or invasive infection. As far as maternal colonization with
U. parvum serovars is concerned, serovar 3 and serovar 6 have
been associated with adverse pregnancy outcome, in particular
(Robertson et al., 1986; Xiao et al., 2011b). Comparative genome
analysis approaches, so far, have been complicated by the limited
knowledge of virulence factors in Ureaplasma per se, phenomens
of size and phase variation in the major virulence factor known,
the so-called multiple banded antigen, and a horizontal gene
transfer oberserved in Ureaplasma (Xiao et al., 2011a; Paralanov
et al., 2012; Silwedel et al., 2017; Sweeney et al., 2017).
Strengths of this study include its prospective character and
its focus on very immature preterm infants, the assessment of
Ureaplasma screening by means of culture and PCR technique
and the differentiation of species and serovars. To the best of
our knowledge, this is the first study to describe the distribution
of U. parvum serovars in a cohort of VLBW infants in Central
Europe and Poland, respectively. Limitations of the present study
are given by its monocentric character. Multicentre studies are
warranted to confirm our current findings. Further limitations
are related to restrictions of secondary endpoint and subgroup
analyses. These findings need confirmation by larger studies
powered to assess the individual outcome measures.
In conclusion, our data may add considerably to the
understanding of Ureaplasma-driven neonatal morbidity,
suggesting that perinatal Ureaplasma exposure may be a driver
in the development of neonatal inflammation and infection as
well as lung injury. Key might be the duration and intensity of
exposure and the addition of a second postnatal injurious hit.
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